Cargando…
Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans
Prevalence of infections by Helicobacter pylori, a pathogen involved in a number of gastrointestinal diseases, remains high in developing countries. Management of infections by eradication is not always an option. Lactobacillus reuteri (L. reuteri) DSMZ17648 (Pylopass™/Lonza) specifically co-aggrega...
Autores principales: | Mehling, Heidrun, Busjahn, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775242/ https://www.ncbi.nlm.nih.gov/pubmed/23917169 http://dx.doi.org/10.3390/nu5083062 |
Ejemplares similares
-
Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study
por: Holz, Caterina, et al.
Publicado: (2014) -
Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial
por: Naghibzadeh, Nooshin, et al.
Publicado: (2022) -
Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
por: Muresan, Iulia Antonia Pop, et al.
Publicado: (2019) -
Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy
por: Ojetti, Veronica, et al.
Publicado: (2012) -
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
por: Dore, Maria P., et al.
Publicado: (2016)